Suzetrigine

Crinetics acquisition completed September 1, 2026 Charles Wagner, EVP, Chief Operating and Financial Officer to take on expanded COO role overseeing integration of Crinetics, effective immediately As part of a planned transition, Jonathan Poole, current SVP Finance, will be appointed EVP, CFO, effective January 1, 2027, and Mr. Wagner will continue as EVP, COO Jasper van Grunsven to join Vertex as EVP, Chief Pain and New Product Planning Officer in September ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the successful completion of the acquisition of Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases. Vertex also announced the expansion of its executive leadership team, in support of the Company’s continued growth and diversification. Completion of Acquisition of Crinetics Pharmaceuticals As announced on July 6, 2026 , Vertex entered into a definitive agreement with Crinetics Pharmaceuticals, whereby Vertex would acquire Crinetics for a total equity value of approximately $10.0 billion, or approximately $8.8 billion net of estimated cash acquired, subject to certain closing conditions. Following the receipt of necessary regulatory clearances and the approval by Crinetics’ shareholders, Vertex completed its acquisition of Crinetics on September 1, 2026. The Crinetics acquisition adds to Vertex’s innovation pipeline, accelerates revenue growth, and enhances the long-term earnings pro the Company. The acquisition brings PALSONIFY ® (paltusotine) and atumelnant, in addition to several other pipeline programs. PALSONIFY is the first and only once-daily oral therapy for acromegaly; it has been launched in the U.S., approved in the EU and is under review by other global regulatory bodies. Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist, is in Phase 3 development for congenital adrenal hyperplasia (CAH) and in Phase 2 development for Cushing’s syndrome. At peak, PALSONIFY and atumelnant have the potential to deliver more than $5 billion in combined annual revenue. The transaction is expected to become accretive to non-GAAP operating income in 2029. ezstandalone.cmd.push(function () { ezstandalone.showAds(132); }); The acquisition is expected to be accounted for as a business combination, and Vertex will provide details on the accounting and financial impacts of the transaction on its third quarter earnings call, scheduled for November 2, 2026. Expansion of Vertex’s Executive Leadership Team Vertex also announced the following additions to its executive leadership team: Effective immediately, Charles Wagner, EVP and Chief Operating and Financial Officer, will expand his COO role to include leadership of the Crinetics integration. The Crinetics acquisition will establish rare endocrine diseases as the next pillar of growth, alongside the Company’s four existing areas of focus in cystic fibrosis, hematology, acute pain and renal. ezstandalone.cmd.push(function () { ezstandalone.showAds(133); }); Effective January 1, 2027, Jonathan Poole, currently Vertex’s SVP Finance, will be appointed EVP, Chief Financial Officer. Mr. Wagner will continue in his expanded role as Vertex’s COO. Mr. Poole will report to Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex, and join the Company’s Executive Committee. Mr. Poole has led Vertex’s global finance organization since March 2020 and has supported Vertex through a period of significant R&D portfolio expansion, global commercial growth and diversification, and the execution and integration of multiple acquisitions. Mr. Poole previously served as CFO of Evelo Biosciences and Genocea Biosciences and SVP of Finance at Shire Plc. Additionally, on September 8, 2026, Jasper van Grunsven will join Vertex as EVP, Chief Pain and New Product Planning Officer, with responsibility for Vertex’s pain franchise, including JOURNAVX ® (suzetrigine) for moderate-to-severe acute pain, as well as global new product planning. Mr. van Grunsven will also report to Dr. Kewalramani and join the Vertex Executive Committee. Mr. van Grunsven is a seasoned biopharmaceutical executive with long and deep experience in sales, marketing and business operations across geographies, disease areas and modalities. Most recently, Mr. van Grunsven served as SVP of Amgen’s Rare Disease portfolio and the Global Customer Capabilities Data & Analytics function. Prior to joining Amgen, van Grunsven held a variety of roles with increasing responsibility at Abbvie, Abbott Laboratories and Nycomed. ezstandalone.cmd.push(function () { ezstandalone.showAds(134); }); “This is an exciting time for Vertex as we enter our next phase of growth and diversification, fueled by the rapid advancement of our R&D pipeline and commercial portfolio,” said Dr. Kewalramani. “With the closing of the Crinetics Pharmaceuticals acquisition, I am pleased to welcome the talented Crinetics team to Vertex and look forward to working together to continue to launch PALSONIFY globally and accelerate the atumelnant program. I also want to congratulate Charlie and Jonathan on their expanded roles and welcome Jasper to the company, as we continue to execute on our strategy to bring more transformative medicines to more patients around the globe.” About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia, acute pain and acromegaly, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including IgA nephropathy, neuropathic pain, APOL1-mediated kidney disease, primary membranous nephropathy, congenital adrenal hyperplasia, ACTH-dependent Cushing's syndrome, autosomal dominant polycystic kidney disease, type 1 diabetes, generalized myasthenia gravis, and myotonic dystrophy type 1. Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 16 consecutive years on Science magazine's Top Employers list and one of Fortune’s 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit or follow us on LinkedIn , Facebook , Instagram , YouTube and X . Special Note Regarding Forward-Looking Statements ezstandalone.cmd.push(function () { ezstandalone.showAds(135); }); This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 related to Vertex and the acquisition of Crinetics by Vertex (the “Transaction”) that are subject to risks, uncertainties and other factors. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the beliefs of Vertex only as of the date of this press release, and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including all statements regarding the intent, belief or current expectation of Vertex and members of its senior management team. Forward-looking statements are not purely historical and may be accompanied by words such as “anticipates,” “may,” “forecasts,” “expects,” “intends,” “plans,” “potentially,” “believes,” “seeks,” “estimates,” and other words and terms of similar meaning. Such statements include the statements made by Reshma Kewalramani, M.D., in this press release, and statements that may relate to, but are not limited to: the benefits of the Transaction; the commercial potential of PALSONIFY and atumelnant, including the potential for more than $5 billion in combined annual revenue; expectations that the Transaction will become accretive to non-GAAP operating income in 2029, will accelerate revenue growth and will enhance the long-term earnings pro Vertex and any assumptions underlying any of the foregoing; and the expectation that Vertex will continue to execute on its strategy to bring more transformative medicines to more patients around the globe. Forward-looking statements are subject to certain risks, uncertainties, or other factors that are difficult to predict and could cause actual events or results to differ materially from those indicated in any such statements due to a number of risks and uncertainties. Those risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include, among other things: risks related to the ability of Vertex to successfully integrate the Crinetics businesses and the possibility that integration may be more difficult, time consuming or costly than expected; that Vertex may not realize the potential benefits of the Transaction; other business effects, including the effects of industry, economic or political conditions outside of the companies’ control; and actual or contingent liabilities related to the Transaction. In addition, the medicine and product candidates that have been acquired by Vertex are subject to all the risks inherent in the drug development process, and there can be no assurance that the development of these product candidates will be commercially successful. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Vertex’s business, particularly those risks listed under the heading “Risk Factors” and the other cautionary factors discussed in Vertex’s periodic reports filed with the Securities and Exchange Commission (the “SEC”), including Vertex’s annual reports on Form 10-K for the year ended December 31, 2025, and subsequent quarterly reports on Form 10-Q and current reports on Form 8-K, all of which are available on the SEC’s website at . You should not place undue reliance on these statements. All forward-looking statements are based on information currently available to Vertex, and Vertex disclaims any obligation to update the information contained in this press release as new information becomes available, except as required by law. (VRTX-GEN) Contacts Investors: InvestorInfo@vrtx.com | +1 617–341–6108 Media: mediainfo@vrtx.com | U.S.: +1 617–341–6992

很多人对基因编辑的认知，还停留在实验室科研阶段。觉得这项顶尖技术距离普通人的生活十分遥远，根本无法落地应用。 但近两年生物医药赛道彻底迎来变革，基因编辑、细胞治疗从科研走向商业化。一边是百亿市场高速扩容、新药密集获批，一边是天价费用、安全隐患难以根除。 今天带大家深度拆解2025基因编辑行业真实现状，看懂技术突破、市场红利、国内外差距以及现存短板。 商业化彻底落地！CRISPR疗法年收入突破1亿美元 2025年堪称基因编辑商业化里程碑之年，行业正式告别概念炒作，迎来实打实的营收增长。 CRISPR Therapeutics旗下核心疗法CASGEVY交出亮眼成绩单，全年收入成功突破1亿美元。 更亮眼的是，这款疗法的治疗患者数量同比暴涨3倍，市场接受度大幅提升。 该疗法主要用于根治镰状细胞病、β地中海贫血两大疑难罕见血液病。 不过个性化治疗的成本极高，单疗程定价高达220万美元，门槛高到绝大多数家庭无法企及。 头部药企的盈利数据同样印证赛道红利，再生元全年营收高达143亿美元。 Vertex单季度营收29.6亿美元，运营利润率超40%，前沿医疗赛道盈利能力极强。 审批全面放开！FDA一年获批55款创新新药疗法 2025年FDA审批节奏大幅提速，全年共计批准55款全新医药产品，刷新近年获批数量新高。 多款颠覆式疗法问世，彻底改写传统疾病治疗方案。 Vertex研发的Journavx极具划时代意义，是20多年首款非阿片类疼痛抑制剂。 以往临床止痛高度依赖阿片类药物，极易引发成瘾、滥用等社会问题。 这款新药打破长期技术僵局，为慢性疼痛患者提供了安全全新的治疗选择。 体内基因编辑技术也实现重大突破，Intellia的NTLA-2001疗法疗效持久稳定。 专门针对转甲状腺素蛋白淀粉样变性疑难病症，为罕见病患者带来治愈希望。 同时基因编辑应用边界持续拓宽，从罕见病正式向癌症、心血管常见病渗透。 这意味着未来普通重大疾病，有望通过基因编辑实现根治，医疗格局迎来巨变。 千亿赛道高速扩容！AI赋能新药研发提速迭代 前沿技术落地带动整个精准医疗赛道爆发式增长，行业估值持续走高。 数据显示，全球基因组学市场估值已接近500亿美元，年增长率稳定超12%。 按照机构测算，2031年全球精准医疗市场规模将飙升至2370亿美元，成长空间巨大。 AI成为行业迭代的核心助推器，彻底改变传统新药研发慢、成本高的痛点。 目前全球已有超530家AI药物研发企业，累计融资突破4200亿美元。 AI能够快速完成靶点筛选、分子设计、临床试验模拟，大幅压缩研发周期。 AI+基因编辑的组合模式，成为当下生物医药领域最核心的创新风口。 光鲜背后暗藏隐患！3大难题制约全民普及 虽然行业数据亮眼、技术不断突破，但基因编辑想要全面普及，依旧困难重重。 第一，长期安全性无法百分百保障 脱靶效应、人体免疫排斥，是基因编辑难以彻底规避的核心风险。 短期临床效果优异，但数年、数十年的长期身体影响，目前依旧缺乏数据支撑。 第二，治疗天价成本难以降低 基因编辑属于高度个性化定制治疗，细胞提取、编辑、回输流程复杂。 无法批量规模化生产，导致成本居高不下，普通患者根本无力承担。 第三，医保支付压力巨大 数百万的单疗程费用，无论是国内还是海外医保体系，都难以大面积覆盖。 技术再好，无法普惠大众，也只能成为少数人的专属医疗资源。 国内企业奋力追赶，与国际龙头差距依旧明显 在全球基因编辑热潮下，国内本土企业也在加速布局、奋起直追。 博雅辑因、瑞风生物、本导基因等本土头部企业持续深耕。 重点围绕地中海贫血、眼科疑难疾病等赛道稳步推进临床试验。 目前国内企业已经实现技术从0到1的突破，顺利进入临床落地阶段。 但客观来看，差距依旧十分明显：海外企业已经实现商业化盈利、规模化治疗。 国内多数企业仍停留在临床试验阶段，管线丰富度、工艺成熟度、盈利能力差距较大。 总结 2025年是基因编辑行业的转折之年，技术落地、营收暴涨、新药频发。 千亿蓝海赛道正式开启，AI赋能让技术迭代速度持续加快。 但安全风险、天价成本、医保限制，依旧是横亘在行业面前的三座大山。 国内企业虽稳步进步，但想要追上国际顶尖水平，依旧需要长期沉淀。 你觉得未来5年，基因编辑疗法能降价走进普通家庭吗？欢迎在评论区留下你的观点。